EUVIMEDEUVIMED entdecken
Systematische Übersicht

Barriers and Enablers for Deprescribing Glucose-Lowering Treatment in Older Adults: A Systematic Review

Marion Mellot, Lina Jawal, Thomas Morel, Jean-Pascal Fournier, Florence Tubach, Jean-Sébastien Cadwallader, Antoine Christiaens, Lorène Zerah

Journal of the American Medical Directors Association · 2024-03 · 25 (3) · 439-447.e18

DOI: 10.1016/j.jamda.2023.11.025 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the American Medical Directors Association, 2024-03. Verfasst von Marion Mellot und 7 weiteren Autor:innen. Beteiligte Einrichtung: Département de gériatrie, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Pitié Salpêtrière, Paris, France. Hauptthemen laut MEDLINE: Deprescriptions, Diabetes Mellitus, Type 2, Medicine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Overtreatment with glucose-lowering treatment (GLT) is frequent and a source of high morbidity and mortality in older adults with type 2 diabetes mellitus (T2DM). This study aimed to identify and synthesize barriers and enablers for deprescribing GLT in older adults (≥65 years) with T2DM. DESIGN: Systematic review of qualitative and mixed-methods studies. SETTING AND PARTICIPANTS: Older adults with T2DM, any participants [patients, health care providers (HCPs), caregivers], any settings. METHODS: Two researchers (and a referred third researcher at all stages) independently screened original articles reporting qualitative and mixed-methods studies exploring barriers and enablers for deprescribing GLT in older adults published during 2010-2023, identified from MEDLINE, Embase, CINAHL, and gray literature. Quality of the included studies was assessed with the Mixed-Methods Appraisal Tool. Verbatim statements on barriers and enablers were extracted, and determinants of behaviors were identified with the Theoretical Domains Framework (TDF) version 2, and related intervention functions (targets for future interventions) were proposed according to the Behavior Change Wheel (BCW). RESULTS: We identified only 4 studies from 2 countries (United States and the Netherlands), all recently published (2019-2023), that primarily reported barriers to GLT deprescribing from interviews or focus groups of patients or HCPs practicing outpatient medicine. Knowledge, fear, poor communication, inertia, and trust with HCPs were the main determinants of behaviors that influenced deprescribing, and education, training, persuasion and environmental restructuring were the main intervention functions for proposing future interventions. Studies did not cover financial aspects, physician characteristics, or caregiver and family viewpoints. CONCLUSIONS AND IMPLICATIONS: The use of a behavioral theory and a validated implementation framework provided a comprehensive approach to identifying barriers and enablers for deprescribing GLT in older adults (≥65 years) with T2DM. The behavioral determinants identified may be useful in tailoring interventions to improve the implementation of GLT deprescribing in older adults in ambulatory settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeprescriptionsDiabetes Mellitus, Type 2MedicineHumansAgedEducational StatusGlucose

Stichwörter der Autor:innen

Behaviordeprescriptiongeriatricshypoglycemic agentsqualitative research

Substanzen

Glucose

Autor:innen und Institutionen

  • Département de gériatrie, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Pitié Salpêtrière, Paris, France.
  • Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
  • Département de Médecine Générale, Faculté de Médecine, Nantes Université, Nantes, France.
  • Département de Médecine Générale, Faculté de Médecine, Nantes Université, Nantes, France; Université Tours-Nantes, INSERM, UMR U1246 SPHERE "Methods in Patient-Centered Outcomes and Health Research", Tours, France.
  • Département de Santé Publique, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Pitié Salpêtrière, Centre de Phar…
  • Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France; Département de Médecine Générale, Sorbonne Université, Paris, France.

Zitieren

APA

Mellot, M., Jawal, L., Morel, T., Fournier, J. P., Tubach, F., Cadwallader, J. S., Christiaens, A., & Zerah, L. (2024). Barriers and Enablers for Deprescribing Glucose-Lowering Treatment in Older Adults: A Systematic Review. Journal of the American Medical Directors Association, 25(3), 439-447.e18. https://doi.org/10.1016/j.jamda.2023.11.025

Vancouver

Mellot M, Jawal L, Morel T, Fournier JP, Tubach F, Cadwallader JS, et al. Barriers and Enablers for Deprescribing Glucose-Lowering Treatment in Older Adults: A Systematic Review. Journal of the American Medical Directors Association. 2024;25(3):439-447.e18. doi:10.1016/j.jamda.2023.11.025

BibTeX
@article{Mellot2024,
  author = {Mellot, Marion and Jawal, Lina and Morel, Thomas and Fournier, Jean-Pascal and Tubach, Florence and Cadwallader, Jean-Sébastien and Christiaens, Antoine and Zerah, Lorène},
  title = {Barriers and Enablers for Deprescribing Glucose-Lowering Treatment in Older Adults: A Systematic Review},
  journal = {Journal of the American Medical Directors Association},
  year = {2024},
  volume = {25},
  number = {3},
  pages = {439--447.e18},
  doi = {10.1016/j.jamda.2023.11.025}
}
Kostenlos starten →